sheep antibody against pgrn (R&D Systems)
Structured Review
![Increased protein levels <t>of</t> <t>PSAP</t> and <t>PGRN</t> within the SFO of SAP-D −/− mice a – b) , Coronal brain section at 0.7–0.8 mm posterior to bregma containing the SFO. a: DAPI staining. a-2: Enlarged view of the white square in a-1. SFO: subfornical organ, 3V: third ventricle. b; Double immunofluorescent staining of PSAP (red) and PGRN (green) in 10-month-old female WT and SAP-D −/− mice. DAPI (blue) staining showed the nuclei ( a and b ). Scale bar, 500 μm ( a and b ). White arrowheads indicate the SFO regions ( b ). c) Cerebral region from 3-, 6-, and 10-month-old male and female mice containing the SFO (0.7–0.8 mm posterior to ∗bregma) used for protein extraction and Western blot ( d – h ) using anti- PSAP, PGRN, and GAPDH antibodies. Quantification normalized to GAPDH expression and represented as the mean ± SD of three mice for each group. and indicate the individual values in each group ( e , f , h ). d – f) PSAP and PGRN protein levels in the SFO were remarkably increased. Their quantification by densitometric analysis is represented in e for male and f for female, respectively. e ) For PSAP/GAPDH, two-way ANOVA revealed a significant main effects of genotype (F(1,24) = 547.7, p < 0.0001, ηp 2 = 0.48, 95 % CI [−74.51, −62.43]), with no effect of age ( p = 0.46) or genotype × age interaction ( p = 0.47). Post-hoc Tukey's tests showed that SAP-D −/− differed from WT at 3 M ( p < 0.0001, Cohen's d = 9.99, 95 % CI [−86.30, −54.96]), 6 M ( p < 0.0001, Cohen's d = 7.24, 95 % CI [−79.04, −47.70]), and 10 M ( p < 0.0001, Cohen's d = 8.77, 95 % CI [−87.09, −55.75]). For PGRN/GAPDH, two-way ANOVA revealed a significant main effect of genotype (F(1,24) = 354.2, p < 0.0001, ηp 2 = 0.48, 95 % CI [−46.39, −37.22]), with no effect of age ( p = 0.73) or genotype × age interaction ( p = 0.76). Post-hoc Tukey's tests showed that SAP-D −/− differed from WT at 3 M ( p < 0.0001, Cohen's d = 7.87, 95 % CI [−52.71, −28.91]), 6 M ( p < 0.0001, Cohen's d = 5.35, 95 % CI [−52.82, −29.02]), and 10 M ( p < 0.0001, Cohen's d = 8.77, 95 % CI [−52.32, −28.52]). f ) For PSAP/GAPDH, two-way ANOVA revealed a significant main effect of genotype (F(1,24) = 611.1, p < 0.0001, ηp 2 = 0.48, 95 % CI [−74.42, −62.95]), with no effect of age ( p = 0.07) or genotype × age interaction (p = 0.07). Post-hoc Tukey's tests showed that SAP-D −/− differed from WT at 3 M ( p < 0.0001, Cohen's d = 9.99, 95 % CI [−86.30, −54.96]), 6 M ( p < 0.0001, Cohen's d = 7.24, 95 % CI [−79.04, −47.70]), and 10 M ( p < 0.0001, Cohen's d = 8.77, 95 % CI [−87.09, −55.75]). For PGRN/GAPDH, two-way ANOVA revealed a significant main effect of genotype (F(1,24) = 273.5, p < 0.0001, ηp 2 = 0.47, 95 % CI [−63.96, −49.76]), with no effect of age ( p = 0.71) or genotype × age interaction (p = 0.70). Post-hoc Tukey's tests showed that SAP-D −/− differed from WT at 3 M ( p < 0.0001, Cohen's d = 7.31, 95 % CI [−73.43, −36.60]), 6 M ( p < 0.0001, Cohen's d = 5.71, 95 % CI [−73.04, −36.22]), and 10 M ( p < 0.0001, Cohen's d = 5.35, 95 % CI [−73.08, −36.26]). g – h ) Comparison of PSAP and PGRN protein expression in the SFO, whole cerebrum, and cerebellum. The quantitative analysis is shown in h . h ) For PSAP/GAPDH, one-way ANOVA revealed a significant effect in SAP-D −/− mice (F(2,6) = 30.06, p = 0.0007, η 2 = 0.90), but not in WT mice ( p = 0.3461). Tukey's post hoc tests showed significant differences for SFO versus cerebellum ( p = 0.0010, Cohen's d = 5.26, 95 % CI [46.80, 119.1]) as well as and cerebrum versus cerebellum ( p = 0.0018, Cohen's d = 9.34, 95 % CI [38.39, 110.6]). There was no significant difference for SFO versus cerebrum ( p = 0.76, Cohen's d = 0.47, 95 % CI [−27.71, 44.54]). For PGRN/GAPDH, one-way ANOVA revealed a significant effect in SAP-D −/− mice (F(2,6) = 54.42, p = 0.0001, η 2 = 0.94), but not in WT mice ( p = 0.6327). Tukey's post hoc tests showed significant differences for SFO versus cerebrum ( p = 0.0005, Cohen's d = 5.43, 95 % CI [26.19, 57.84]) as well as and SFO versus cerebellum ( p = 0.0005, Cohen's d = 5.43, 95 % CI [26.19, 57.84]), but not for cerebrum versus cerebellum ( p = 0.3274, Cohen's d = 6.06, 95 % CI [−7.72, 23.92]). ns: no significant difference. ∗∗∗∗ p < 0.0001. ∗∗∗ p < 0.001. ∗∗ p < 0.01.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0004/pmc12720004/pmc12720004__gr1.jpg)
Sheep Antibody Against Pgrn, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 94 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sheep+anti+mouse+pgrn/Mouse+Progranulin%2FPGRN+Antibody/pmc12720004-219-19-27
Average 93 stars, based on 94 article reviews
Images
1) Product Images from "Accumulation of prosaposin and progranulin around the subfornical organ induces polydipsia in SAP-D-deficient mice"
Article Title: Accumulation of prosaposin and progranulin around the subfornical organ induces polydipsia in SAP-D-deficient mice
Journal: Biochemistry and Biophysics Reports
doi: 10.1016/j.bbrep.2025.102388
Figure Legend Snippet: Increased protein levels of PSAP and PGRN within the SFO of SAP-D −/− mice a – b) , Coronal brain section at 0.7–0.8 mm posterior to bregma containing the SFO. a: DAPI staining. a-2: Enlarged view of the white square in a-1. SFO: subfornical organ, 3V: third ventricle. b; Double immunofluorescent staining of PSAP (red) and PGRN (green) in 10-month-old female WT and SAP-D −/− mice. DAPI (blue) staining showed the nuclei ( a and b ). Scale bar, 500 μm ( a and b ). White arrowheads indicate the SFO regions ( b ). c) Cerebral region from 3-, 6-, and 10-month-old male and female mice containing the SFO (0.7–0.8 mm posterior to ∗bregma) used for protein extraction and Western blot ( d – h ) using anti- PSAP, PGRN, and GAPDH antibodies. Quantification normalized to GAPDH expression and represented as the mean ± SD of three mice for each group. and indicate the individual values in each group ( e , f , h ). d – f) PSAP and PGRN protein levels in the SFO were remarkably increased. Their quantification by densitometric analysis is represented in e for male and f for female, respectively. e ) For PSAP/GAPDH, two-way ANOVA revealed a significant main effects of genotype (F(1,24) = 547.7, p < 0.0001, ηp 2 = 0.48, 95 % CI [−74.51, −62.43]), with no effect of age ( p = 0.46) or genotype × age interaction ( p = 0.47). Post-hoc Tukey's tests showed that SAP-D −/− differed from WT at 3 M ( p < 0.0001, Cohen's d = 9.99, 95 % CI [−86.30, −54.96]), 6 M ( p < 0.0001, Cohen's d = 7.24, 95 % CI [−79.04, −47.70]), and 10 M ( p < 0.0001, Cohen's d = 8.77, 95 % CI [−87.09, −55.75]). For PGRN/GAPDH, two-way ANOVA revealed a significant main effect of genotype (F(1,24) = 354.2, p < 0.0001, ηp 2 = 0.48, 95 % CI [−46.39, −37.22]), with no effect of age ( p = 0.73) or genotype × age interaction ( p = 0.76). Post-hoc Tukey's tests showed that SAP-D −/− differed from WT at 3 M ( p < 0.0001, Cohen's d = 7.87, 95 % CI [−52.71, −28.91]), 6 M ( p < 0.0001, Cohen's d = 5.35, 95 % CI [−52.82, −29.02]), and 10 M ( p < 0.0001, Cohen's d = 8.77, 95 % CI [−52.32, −28.52]). f ) For PSAP/GAPDH, two-way ANOVA revealed a significant main effect of genotype (F(1,24) = 611.1, p < 0.0001, ηp 2 = 0.48, 95 % CI [−74.42, −62.95]), with no effect of age ( p = 0.07) or genotype × age interaction (p = 0.07). Post-hoc Tukey's tests showed that SAP-D −/− differed from WT at 3 M ( p < 0.0001, Cohen's d = 9.99, 95 % CI [−86.30, −54.96]), 6 M ( p < 0.0001, Cohen's d = 7.24, 95 % CI [−79.04, −47.70]), and 10 M ( p < 0.0001, Cohen's d = 8.77, 95 % CI [−87.09, −55.75]). For PGRN/GAPDH, two-way ANOVA revealed a significant main effect of genotype (F(1,24) = 273.5, p < 0.0001, ηp 2 = 0.47, 95 % CI [−63.96, −49.76]), with no effect of age ( p = 0.71) or genotype × age interaction (p = 0.70). Post-hoc Tukey's tests showed that SAP-D −/− differed from WT at 3 M ( p < 0.0001, Cohen's d = 7.31, 95 % CI [−73.43, −36.60]), 6 M ( p < 0.0001, Cohen's d = 5.71, 95 % CI [−73.04, −36.22]), and 10 M ( p < 0.0001, Cohen's d = 5.35, 95 % CI [−73.08, −36.26]). g – h ) Comparison of PSAP and PGRN protein expression in the SFO, whole cerebrum, and cerebellum. The quantitative analysis is shown in h . h ) For PSAP/GAPDH, one-way ANOVA revealed a significant effect in SAP-D −/− mice (F(2,6) = 30.06, p = 0.0007, η 2 = 0.90), but not in WT mice ( p = 0.3461). Tukey's post hoc tests showed significant differences for SFO versus cerebellum ( p = 0.0010, Cohen's d = 5.26, 95 % CI [46.80, 119.1]) as well as and cerebrum versus cerebellum ( p = 0.0018, Cohen's d = 9.34, 95 % CI [38.39, 110.6]). There was no significant difference for SFO versus cerebrum ( p = 0.76, Cohen's d = 0.47, 95 % CI [−27.71, 44.54]). For PGRN/GAPDH, one-way ANOVA revealed a significant effect in SAP-D −/− mice (F(2,6) = 54.42, p = 0.0001, η 2 = 0.94), but not in WT mice ( p = 0.6327). Tukey's post hoc tests showed significant differences for SFO versus cerebrum ( p = 0.0005, Cohen's d = 5.43, 95 % CI [26.19, 57.84]) as well as and SFO versus cerebellum ( p = 0.0005, Cohen's d = 5.43, 95 % CI [26.19, 57.84]), but not for cerebrum versus cerebellum ( p = 0.3274, Cohen's d = 6.06, 95 % CI [−7.72, 23.92]). ns: no significant difference. ∗∗∗∗ p < 0.0001. ∗∗∗ p < 0.001. ∗∗ p < 0.01.
Techniques Used: Staining, Protein Extraction, Western Blot, Expressing, Comparison
Figure Legend Snippet: Increased PSAP and PGRN immunostaining in the SFO and its surrounding tissues in SAP-D −/− mice a) Double immunofluorescent staining of PSAP (red) and PGRN (green) around the SFO in 10-month-old female WT and SAP-D −/− mice. The white dotted lines enclose the SFO. b ) enlarged white ⅰ-iv squares in a, as indicated. White arrowheads indicate co-staining with anti-PGRN and PSAP antibodies. Open arrowheads indicate staining with PGRN alone. Nuclei are labeled by DAPI (blue) staining. All scale bars, 20 μm.
Techniques Used: Immunostaining, Staining, Labeling
Figure Legend Snippet: Infiltration of CD68-positive activated microglia/macrophages co-expressing PSAP and PGRN into the SFO and surrounding tissues a – b) Double immunofluorescent staining of PGRN (green) and CD68 (red) around the SFO in 10-month-old-female WT and SAP-D −/− mice. b , Magnified images of the indicated white squares in a . ⅰ: SFO, ⅱ: Fornix, and ⅲ: Perivascular, bv: blood vessel. c ) Quantification of PGRN- and/or CD68-staining in the SFO and surrounding areas in WT and SAP-D −/− mice. Data are shown as the mean ± SD (n = 3). The left panel presents a stacked bar chart, whereas the right panel shows the individual data values in a bar chart format. d – h ) Triple immunofluorescent staining of PSAP (red), PGRN (green), and CD68 (cyan) around the SFO in 10-month-old-female SAP-D −/− mice. e) Magnified images of the indicated white squares in d) ⅳ: Boundary, ⅴ: Fornix, and ⅵ: Perivascular. White arrowheads indicate triple co-staining with PSAP, PGRN, and CD68. Open arrowheads indicate PGRN signals alone. Co-localization rates of CD68 positive areas in PSAP ( f ), PGRN ( g ), and PSAP-PGRN staining areas ( h ) around the SFO of SAP-D −/− mice, respectively. f-h ) The left panel presents a stacked bar chart, whereas the right panel presents the individual data values in a bar chart format. Data are shown as mean ± SD (n = 3). Nuclei are labeled by DAPI (blue) staining. All scale bars, 50 μm.
Techniques Used: Expressing, Staining, Labeling
Figure Legend Snippet: Lysosomal localization of PSAP and PGRN expression around the SFO a) Immunofluorescence staining of LAMP1 (green) around the SFO in 10-month-old female WT and SAP-D −/− mice. Nuclei are labeled by DAPI (blue) staining. b) Quantification of LAMP1-stained areas in ( a ) relative to WT (%). The results of Student's t-tests for each panel are as follows: left panel, p = 0.0059, Cohen's d = 2.35 (95 % CI: 15.89, 67.66); and right panel: p = 0.0061, Cohen's d = 2.33 (95 % CI: 51.06, 220.89). Data are shown as the mean ± SD (n = 5). c) Triple immunofluorescent staining of PSAP (red), PGRN (green), and LAMP1 (cyan) around the SFO of 10-month-old female SAP-D −/− mice. Enlarged images indicated by the white squares (ⅰ-iv) were shown in c. d) Localization rate of PGRN or PSAP to LAMP1 in the SFO. The results of Student's t-tests for each panel are as follows: left panel, p = 0.0008, Cohen's d = 2.24 (95 % CI: -40.90, -13.73); and right panel, p = 0.2341, Cohen's d = 0.64 (95 % CI: 26.80, 7.17). Data are shown as the mean ± SD (n = 6 for WT-SFO and n = 8 for SAP-D −/− -SFO). e) Same experiment as in (c) on microglia/macrophage co-expressing PSAP and PGRN, or PGRN only, in the boundary and fornix regions of SAP-D −/− mice. Single image for each antibody was shown in white, while double or triple merged images were presented with red (PSAP or PGRN), green (LAMP1 or PGRN), or cyan (LAMP1) as indicated. and indicate the individual values in each group (b and d). ns: no significant difference. ∗∗∗ p < 0.001. ∗∗ p < 0.01. All scale bars, 10 μm.
Techniques Used: Expressing, Immunofluorescence, Staining, Labeling
Related Articles
Biomarker Discovery:Article Title: Reduced progranulin increases tau and α-synuclein inclusions and alters mouse tauopathy phenotypes via glucocerebrosidase Article Snippet: .. Western Blot:Article Title: Progranulin inhibits phospholipase sPLA2-IIA to control neuroinflammation Article Snippet: .. The following antibodies were used in this study: Rabbit anti-GFP antibody was a gift from Professor Anthony Bretscher; Mouse anti-Myc (9E10) (Sigma, 1:1000 for western blot), mouse anti-GAPDH (Proteintech Group, 1:10000 for western blot), mouse anti-Transferrin (Proteintech Group, 1:1000 for western blot), rat anti-mouse LAMP1 (1D4B) (BD Biosciences, 553793, 1:300 for immunostaining), Article Title: sPLA2-IIA modifies progranulin deficiency phenotypes in mouse models Article Snippet: Mouse PGRN construct was cloned into pSecTag2B vector (Invitrogen) with an N-terminal FLAG-His tag (Flag-mPGRN). .. The following antibodies were used in this study: mouse anti-Myc (9E10) (Sigma, 1:1000 for western blot), mouse anti-GAPDH (Proteintech Group, 60004-1-Ig, 1:10000 for western blot), mouse anti-actin (Proteintech Group, 66009-1-Ig, 1:5000 for western blot), rat anti-mouse LAMP1 (1D4B) (BD Biosciences, 553793, 1:300 for immunostaining), Article Title: sPLA2-IIA modifies progranulin deficiency phenotypes in mouse models. Article Snippet: Mouse PGRN construct was cloned into pSecTag2B vector (Invitrogen) with an N-terminal FLAG-His tag (Flag-mPGRN). .. The following antibodies were used in this study: mouse anti-Myc (9E10) (Sigma, 1:1000 for western blot), mouse anti-GAPDH (Proteintech Group, 60004-1-Ig, 1:10000 for western blot), mouse anti-actin (Proteintech Group, 66009-1-Ig, 1:5000 for western blot), rat antimouse LAMP1 (1D4B) (BD Biosciences, 553793, 1:300 for immunostaining), Immunostaining:Article Title: Progranulin inhibits phospholipase sPLA2-IIA to control neuroinflammation Article Snippet: .. The following antibodies were used in this study: Rabbit anti-GFP antibody was a gift from Professor Anthony Bretscher; Mouse anti-Myc (9E10) (Sigma, 1:1000 for western blot), mouse anti-GAPDH (Proteintech Group, 1:10000 for western blot), mouse anti-Transferrin (Proteintech Group, 1:1000 for western blot), rat anti-mouse LAMP1 (1D4B) (BD Biosciences, 553793, 1:300 for immunostaining), Article Title: sPLA2-IIA modifies progranulin deficiency phenotypes in mouse models Article Snippet: Mouse PGRN construct was cloned into pSecTag2B vector (Invitrogen) with an N-terminal FLAG-His tag (Flag-mPGRN). .. The following antibodies were used in this study: mouse anti-Myc (9E10) (Sigma, 1:1000 for western blot), mouse anti-GAPDH (Proteintech Group, 60004-1-Ig, 1:10000 for western blot), mouse anti-actin (Proteintech Group, 66009-1-Ig, 1:5000 for western blot), rat anti-mouse LAMP1 (1D4B) (BD Biosciences, 553793, 1:300 for immunostaining), Article Title: sPLA2-IIA modifies progranulin deficiency phenotypes in mouse models. Article Snippet: Mouse PGRN construct was cloned into pSecTag2B vector (Invitrogen) with an N-terminal FLAG-His tag (Flag-mPGRN). .. The following antibodies were used in this study: mouse anti-Myc (9E10) (Sigma, 1:1000 for western blot), mouse anti-GAPDH (Proteintech Group, 60004-1-Ig, 1:10000 for western blot), mouse anti-actin (Proteintech Group, 66009-1-Ig, 1:5000 for western blot), rat antimouse LAMP1 (1D4B) (BD Biosciences, 553793, 1:300 for immunostaining), other:Article Title: Progranulin deficiency does not exacerbate TDP-43 pathology in TDP-43 transgenic mouse models Article Snippet: The following antibodies were used in this study: rabbit anti-IBA-1 (Wako, 01919741), goat anti-AIF-1/Iba1 (Novus Biologicals, NB100-1028), rat anti-CD68 (Bio-Rad, MCA1957), mouse anti-GFAP (Cell signaling, 3670S), rabbit anti-TDP43 (Proteintech Group, 12892-1-AP (C-terminal) and 10782-2-AP (N-terminal)), rabbit anti-phospho-TDP-43 (Ser409/410) (Proteintech group, 80007-1-RR), mouse anti-PLP (Millipore, MAB388), mouse anti-MBP (Millipore, SMI-99), rabbit anti-MAG (Proteintech Group, 14386-1-AP), |

